Selinexor

Selinexor 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Myelofibrosis、Post-polycythemia Vera Myelofibrosis、Post-essential Thrombocythemia Myelofibrosis。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Selinexor 研究

• Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial

  II 期招募中美国NCT05333458

• A Trial of Selinexor, Ruxolitinib and Methylprednisolone

  I 期招募中美国NCT06225310

• Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

  I 期招募中美国NCT07200102

• Second-line Immunotherapy for ES-SCLC

  不适用招募中中国NCT06853678

• A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL

  I 期 / II 期招募中中国NCT06966154

• Golidocitinib Combined With Selinexor for CAEBVD

  II 期 / III 期招募中中国NCT07369739

• A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

  II 期招募中美国NCT04661137

• A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

  III 期招募中中国NCT07579234

• Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

  I 期 / II 期招募中美国NCT07479979

• HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

  II 期招募中美国NCT06822972

• A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

  III 期招募中中国NCT07623798

• Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

  II 期招募中中国NCT05833893

• Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study

  II 期招募中中国NCT07002099

• Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients

  不适用招募中意大利NCT06933277

• A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

  II 期招募中GreeceIsraelNCT04414475

• Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study

  不适用招募中中国NCT07514052

• A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

  II 期招募中美国NCT05985161

• Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)

  II 期招募中西班牙NCT06114004

• Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

  II 期招募中中国NCT07523737

• A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

  III 期招募中中国NCT07011056

• Selinexor and Backbone Treatments of Multiple Myeloma Patients

  I 期 / II 期招募中美国加拿大NCT02343042

• Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

  II 期招募中美国NCT05983276

• A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

  III 期招募中中国NCT07138209

• A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

  II 期招募中美国比利时Bulgaria加拿大NCT05980806

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。